Matthew Lin is a health care deal lawyer that handles complex corporate transactions and related regulatory issues. Matt’s practice draws on his understanding of the unique and rapidly developing legal risks facing members of the health care industry. He manages acquisitions and divestitures of various health care providers, including:

  • Hospitals
  • Physician practices
  • Home health and hospice agencies
  • Long-term care facilities
  • Optometry
  • Physical therapy
  • Behavioral health 

Matt advises clients on the regulatory challenges that impact health care deals, such as fraud and abuse laws, corporate practice of medicine and licensure issues. Matt has extensive experience in managing the potential disclosure of health care deals to state regulators like California’s Office of Health Care Affordability (OHCA) and the Oregon Health Authority (OHA) under state “Mini-HSR” laws.

Before joining Polsinelli, Matt worked on white collar investigations and litigation matters at an international law firm. His work involved matters critical to the health care and life sciences industries, such as the Anti-Kickback Statute, the Federal and California False Claims Acts, health care fraud, the California Knox Keene Act and the Controlled Substances Act. During law school, Matt externed with the Criminal Division of the United States Attorney’s Office for the Central District of California. He also served on the boards of the Harvard Asian Pacific American Law Students Association and the Harvard Prison Legal Assistance Project.

Education

  • Harvard Law School (J.D., 2019)
    • California State University (B.A., summa cum laude, 2015)

      Bar Admission

      • California

      Professional Affiliations

      • Leadership Council on Legal Diversity (LCLD)
        • 2025 Pathfinder
      • Asian Pacific American Bar Association of Los Angeles County
        • Board Member
      • American Health Law Association
      Publications
      All Publications
      California Attorney General and California Medical Association Advocate for Competing Interpretations of Corporate Practice of Medicine Laws That May Reshape PC/MSO Structures
      Key Takeaways The pending Art Center case could significantly reshape California’s “friendly PC” / PC-MSO model, particularly regarding whether MSOs can remove and replace physician shareholders. The California AG and CMA present competing interpretations of CPOM: the AG favors a strict prohibition on removal rights, while the CMA supports a fact-specific analysis focused on actual control over clinical decision-making. Health care stakeholders should proactively review and potentially revise PC/MSO agreements, as increased enforcement risk and evolving legal standards may render common provisions — especially physician removal rights — unlawful. Two amicus briefs filed in a matter before the California Court of Appeal illustrate potential futures for the friendly PC structure and enforcement against the corporate practice of medicine (CPOM). On March 30, 2026, the California
      Read More
      Governor Newsom Embraces Tighter Requirements on Private Equity and Hedge Fund Investments in California Health Care By Signing AB 1415 and SB 351
      This month, Governor Newsom signed AB 1415 and SB 351 into law, two bills that will enhance the requirements on investments by private equity groups and hedge funds in California health care. As detailed below, AB 1415 will significantly expand the reach of the Office of Health Care Affordability (OHCA), and SB 351 further codifies restrictions on the role that private equity groups and hedge funds can play in the management of medical and dental practices. Both bills will go into effect on January 1, 2026. Collectively, these measures add to the burdens and scrutiny faced by private equity and hedge funds that invest in the health care sector, although other health care stakeholders may feel the ripple effects as well.  Many
      Read More